Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass

British Journal of Anaesthesia

Volumn 112, Issue 2, 2014, Pages 319-327

  Guzzetta, N A ^a,b   Szlam, F ^a   Kiser, A S ^a   Fernandez, J D ^b   Szlam, A D ^c   Leong, T ^d   Tanaka, K A ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c CITY COLLEGE OF NEW YORK   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

bleeding; cardiopulmonary bypass; coagulation anticoagulation; neonate; thrombin

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; CRYOPRECIPITATE; DRUG BLOOD LEVEL; EX VIVO STUDY; FEMALE; HEART SURGERY; HEMOSTASIS; HUMAN; MALE; NEWBORN; NEWBORN SURGERY; PLASMA; PLASMA TRANSFUSION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; UMBILICAL CORD BLOOD;

BLEEDING; CARDIOPULMONARY BYPASS; COAGULATION/ANTICOAGULATION; NEONATE; THROMBIN;

BLOOD COAGULATION FACTORS; CARDIOPULMONARY BYPASS; COMPUTER SIMULATION; FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; INFANT, NEWBORN; MALE; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; THROMBIN;

EID: 84892774201     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet355     Document Type: Article

References (32)

1. Petaja J, Lundstrom U, Leijala M, Peltola K, Siimes M. Bleeding and use of blood products after heart operations in infants. J ThoracCardiovasc Surg 1995; 109: 524-9
2. Willems A, Harrington K, Lacroix J, et al. Comparison of two red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis. Crit Care Med 2010; 38: 649-56
3. Martin K, Gertler R, Liermann H, et al. Switch from aprotinin to 1-aminocaproic acid: impact on blood loss, transfusion, and clinical outcome in neonates undergoing cardiac surgery. Br J Anaesth 2011; 107: 934-9
4. Guzzetta NA, Russell IA, Williams GD. AReviewof the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients. Anesth Analg 2012; 115: 364-78
5. Cote CJ, Grabowski EF, StowellCP. Strategies for blood product management and reducing transfusions. In: Cote CJ, Lerman J, Todres ID, eds. A Practice of Anesthesia for Infants and Children, 4th Edn). Philadelphia, PA: Saunders, an imprint of Elsevier, Inc. , 2009; 198-200
6. Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67: 3-12
7. van 't Veer C, Golden NJ, Kalfatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. J Biol Chem 1997; 272: 7983-94
8. Luan D, ZaiM, Varner JD. Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLos Comp Biol 2007; 3: e142
9. Szlam F, Luan D, Bollinger D, et al. Anti-factor IXa aptamer reduces propagation of thrombingeneration in plasma anticoagulated with warfarin. Thromb Res 2010; 125: 432-7
10. Luan D, Szlam F, Tanaka KA, Barie PS, Varner JD. Ensembles of uncertain mathematical models can identify network response to therapeutic interventions. Mol Biosyst 2010; 6: 2272-86
11. Guzzetta NA, Bajaj T, Fazlollah T, et al. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg 2008; 106: 419-25
12. Hornykewycz S, Odegard KC, Castro RA, Zurakowski D, Pigula F, DiNardo JA. Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants. Paediatr Anaesth 2009; 19: 854-61
13. Levy JH, Tanaka KA, DietrichW. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109: 918-26
14. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24
15. Kuhle S, Male C, Mitchell L. Developmental hemostasis: pro-and anticoagulant systems during childhood. Semin Thromb Hemost 2003; 29: 329-37
16. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104
17. Kaspereit F, HoffmannS, Pragst I, Dickneite G. Prothrombincomplex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model. Br J Anaesth 2010; 105: 576-82
18. Mitterlechner T, Innerhofer P, Streif W, et al. Prothrombin complex concentrate and recombinant prothrombin alone or in combinantion with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model. J Thromb Haemost 2011; 9: 729-37
19. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-13
20. Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haemotol 2006; 134: 314-9
21. Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 1989; 62: 788-91
22. Szlam F, Sreeram G, Solomon C, Levy JH, Molinaro RJ, Tanaka KA. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux. Thromb Res 2011; 127: 135-140
23. Mitrophanov AY, Reifman J. Kinetic modeling sheds light on the modeof action of recombinant factor VIIa onthrombingeneration. Thromb Res 2011; 128: 381-90
24. Martin K, Gertler R, MacGuill M, et al. Replacement of aprotinin by 1-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome. Br J Anaesth 2013; 110: 615-21
25. Nuttall GA, Oliver WC, Ereth H, Santrach PJ. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 815-23
26. Costello JM, Graham DA, Morrow DF, et al. Risk factors for surgical site infection after cardiac surgery in children. Ann Thorac Surg 2010; 89: 1833-42
27. Dickneite G, Dorr B, Kaspereit F, Tanaka KA. Prothrombin complex concentrate versus recombinant factor VIIafor reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma 2010; 68: 1151-7
28. Ogawa S, Ohnishi T, Hosokawa K, Szlam F, Chen EP, Tanaka KA. Haemodilution-induced changes in coagulation and effects of haemostatic components under flow conditions. Br J Anaesth 2014; 111: 1013-23
29. Lutsey PL, Folsom AR, Heckbert SR, Cushman M. Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost 2009; 7: 1639-48
30. Manlhiot C, Menjak IB, Brandao LR, et al. Risk, clinical features, and outcomes of thrombosis associated with pediatric cardiac surgery/ clinical perspective. Circulation 2011; 124: 1511-9
31. MannKG. Thrombingenerationinhemorrhage controlandvascular occlusion. Circulation 2011; 124: 225-35
32. Ogawa S, Szlam F, Ohnishi T, Molinaro RJ, Hosokawa K, Tanaka KA. A comparative study of prothrombin complex concentrates and fresh-frozen plasmaforwarfarin reversal under static andflowconditions. Thromb Haemost 2011; 106: 1215-23